Oral ivermectin to treat scabies: a comparison of two different regimens.

Autor: Balestri R; Division of Dermatology, STI Clinic, Trento Hospital, Trento, Italy., Magnano M; Division of Dermatology, STI Clinic, Trento Hospital, Trento, Italy., Infusino SD; Division of Dermatology, STI Clinic, Trento Hospital, Trento, Italy., Girardelli CR; Division of Dermatology, STI Clinic, Trento Hospital, Trento, Italy., Ioris T; Division of Dermatology, STI Clinic, Trento Hospital, Trento, Italy., Rech G; Division of Dermatology, STI Clinic, Trento Hospital, Trento, Italy.
Jazyk: angličtina
Zdroj: Clinical and experimental dermatology [Clin Exp Dermatol] 2023 Mar 01; Vol. 48 (3), pp. 232-234.
DOI: 10.1093/ced/llac092
Abstrakt: As Sarcoptes scabiei is becoming less sensitive to permethrin, clinicians have started to prescribe oral ivermectin (OI) as a first-line treatment. Guidelines suggest OI 200 µg kg-1 as two doses, 1 week apart. However, the black box of the ivermectin registered in Italy recommends a single dose. To compare these two regimens, we collected 71 cases of scabies and treated them according to this protocol [single-dose group (SDG)]. This population was compared to 68 patients who received two doses 1 week apart [double-dose group (DDG)]. Clearance of the disease was achieved in 98% of DDG patients. In the SDG, treatment was successful in only 58% of patients. This study confirms that the absence of a second intake of OI is one of the main predictors of treatment failure (P < 0.001), which may also increase the likelihood of emerging resistance in S. scabiei.
Competing Interests: Conflict of interest: The authors declare that they have no conflicts of interest.
(© The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje